Clinical trials: Haemodialysis
Chronic Kidney Disease Stage V, Hemodialysis
Post Marketing Observational Study on Paricalcitol IV Administered to Venezuelan Patients
This study was designed to evaluate the effectiveness, safety, and impact on quality of life when paricalcitol (Zemplar® intravenous [IV]) is administered in Venezuelan patients on hemodialysis who are at risk of developing…
- Trial name
- NCT01758289
- Where
- 8 sites in Venezuela
- Volunteers
- 105 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
End Stage Renal Disease
A Safety Study of Pentoxifylline for the Treatment of Anemia
Chronic kidney disease (CKD) patients have increased levels of inflammation and oxidative stress, which in turn contribute to anemia and cardiovascular disease.
- Trial name
- NCT01102218
- Testing
- Erythropoietin, Pentoxifylline
- Where
- 10 sites in United States
- Volunteers
- 48 people
- Sponsor
- Fresenius Medical Care North America
Chronic Renal Failure, Chronic Kidney Disease
Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD
The purpose of this study was to evaluate the long term safety and tolerability of peginesatide for the maintenance of hemoglobin in participants with chronic kidney disease (CKD) who had received at least 24 weeks of…
- Conditions
- Chronic Renal Failure, Chronic Kidney Disease, Anemia
- Trial name
- NCT00372489
- Testing
- peginesatide
- Where
- 9 sites in United States
- Volunteers
- 81 people
- Sponsor
- Affymax
End Stage Kidney Disease
The Vascutek Rapidax™ II Post Market Surveillance Registry
Multicentre, prospective, observational post-market registry. To monitor and collect data on the post-market clinical safety and performance of the Vascutek Rapidax II Vascular Access Graft.
- Trial name
- NCT01977508
- Testing
- ePTFE vascular access grafts
- Where
- 3 sites in Germany
- Volunteers
- 24 people
- Sponsor
- Vascutek Ltd.
End Stage Renal Disease, Inflammation
Inflammation and Nutritional Parameters in Hemodialysis Patients Using Reprocessed Dialyzers
The study is a prospective cohort trial utilizing sequential laboratory results from excess serum obtained from hemodialysis patients (acting as their own controls).
- Trial name
- NCT00440908
- Where
- 2 sites in United States
- Volunteers
- 2,500 people
- Sponsor
- Fresenius Medical Care North America
Septic Shock
Continuous Hemodialysis With an Enhanced Middle Molecule Clearance Membrane
This study aims to demonstrate equivalence in terms of molecule removal between continuous hemodialysis using an "enhanced middle molecule clearance" membrane(Ultraflux EMiC2) and continuous hemofiltration using a standard…
- Trial name
- NCT01067313
- Testing
- Dialyzer Ultraflux EMiC2, Dialyzer Ultraflux AV1000S
- Where
- France
- Volunteers
- 24 people
- Sponsor
- Fresenius Medical Care France
Renal Insufficiency
Clinical Assessment of a New Catheter Surface Coating With Antimicrobial Properties
The study investigates the efficacy of a catheter with antibacterial surface coating in preventing central venous catheter related infection and the effect of an intensive hygiene and catheter care education of the nursing staff…
- Trial name
- NCT00621712
- Testing
- GamCath® central venous catheter, GamCath Dolphin® Protect central venous catheter
- Where
- Germany
- Volunteers
- 90 people
- Sponsor
- Vantive Health LLC
Chronic Kidney Failure
An Evaluation of the Long-term Safety of Magnesium Iron Hydroxycarbonate
Fermagate is a phosphate binder that absorbs phosphate from food, reducing the amount that the body can absorb. The purpose of this study it to look at the safety of fermagate over longer periods of time.
- Trial name
- ALCON (NCT00358722)
- Testing
- Fermagate
- Where
- 15 sites in United States, United Kingdom
- Volunteers
- 44 people
- Sponsor
- Ineos Healthcare Limited
Renal Anemia
Study to Compare the Safety and Efficacy of UB-851 and Eprex®
The primary objective of this study is to evaluate a 1:1 dose conversion from Eprex® to UB-851 in terms of clinical efficacy and safety in subjects with chronic renal failure receiving hemodialysis.
- Trial name
- NCT02708914
- Testing
- UB-851, Eprex
- Volunteers
- 269 people
- Sponsor
- UBI Pharma Inc.
Arteriovenous Graft
An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Placement of an Arteriovenous Graft to Facilitate Hemodialysis Access
A study to evaluate the efficacy of SRM003 treatment versus participating sites' standard practice treatment in extending the duration of primary patency after arteriovenous graft surgery in subjects with end-stage renal disease.
- Trial name
- NCT01806584
- Testing
- SRM003, Participating Site's standard practice
- Where
- 46 sites in United States
- Volunteers
- 32 people
- Sponsor
- Shire
Renal Failure, Acute Renal Failure
Premarket Clinical Safety Assessment of the ELISIO™-HX
The primary safety objective of this study is to evaluate the safety of the use of the high-permeability hemodialyzer series ELISIO™-HX, by showing that the pre-dialysis albumin levels are not affected using the investigational…
- Conditions
- Renal Failure, Acute Renal Failure, Chronic Renal Failure, Chronic Kidney Diseases
- Trial name
- NCT07058909
- Testing
- ELISIO™-HX Dialyzer
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Nipro Medical Corporation
Acute Kidney Injury, Fluid Overload
Prospective, Multi-center, Single-arm, Observational Study. US FDA 522 Pediatric Post Market Surveillance Study.
The post market surveillance study will employ a prospective, multi-center, single-arm, observational design to capture data on children who undergo CRRT using the Carpediem™ system.
- Trial name
- NCT04608149
- Testing
- Carpediem System
- Where
- 6 sites in United States
- Volunteers
- 36 people
- Sponsor
- Mozarc Medical US LLC
Peripheral Artery Disease, Popliteal Aneurysm
Observational GORE® VIABAHN® Endoprosthesis With PROPATEN Bioactive Surface Global Registry
Collect real-world post-market clinical follow-up data on patients treated with the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX)
- Conditions
- Peripheral Artery Disease, Popliteal Aneurysm, Hemodialysis Access, Visceral Artery Aneurysms
- Trial name
- NCT04907240
- Testing
- GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX)
- Where
- 26 sites in Belgium, France and 7 more
- Volunteers
- 614 people
- Sponsor
- W.L.Gore & Associates
Anemia, Chronic Kidney Disease
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
The primary objectives of this study are the following: 1. To test if the proportion of participants achieving a hemoglobin value greater than or equal to 10.0 g/dL at any time point after the first dose during the study is…
- Conditions
- Anemia, Chronic Kidney Disease, Kidney Disease
- Trial name
- NCT00436748
- Testing
- Darbepoetin Alfa
- Where
- 67 sites in United States, Belgium and 8 more
- Volunteers
- 116 people
- Sponsor
- Amgen
Kidney Disease, Chronic Kidney Disease
Study Evaluating Darbepoetin Alfa in Subjects With Chronic Kidney Disease (CKD) Receiving Dialysis
The proposed study is designed to test a novel dosing paradigm that would facilitate the treatment of anemia in CKD patients on dialysis.
- Trial name
- NCT00096915
- Testing
- Darbepoetin Alfa
- Volunteers
- 110 people
- Sponsor
- Amgen
Chronic Kidney Disease
Cross-Over Study of Sevelamer Hydrochloride and Sevelamer Carbonate
This is a double-blind, randomized, cross-over study conducted at centers within the United States. The study consists of five periods: an up to two-week Screening Period, a 5-week Run-In Period, two eight-week study treatment…
- Trial name
- NCT00440648
- Testing
- sevelamer carbonate, sevelamer hydrochloride, sevelamer hydrochloride, sevelamer carbonate
- Where
- 15 sites in United States
- Volunteers
- 80 people
- Sponsor
- Genzyme, a Sanofi Company
Chronic Kidney Disease
Clinical Pharmacology Study of TS-143 in Nondialysis and Hemodialysis Patients With Chronic Kidney Disease
To evaluate the safety, pharmacokinetics, and pharmacodynamics in nondialysis (ND) and hemodialysis (HD) subjects with Chronic Kidney Disease (CKD) who receive a single administration of TS-143.
- Trial name
- NCT03581071
- Testing
- TS-143
- Where
- Japan
- Volunteers
- 29 people
- Sponsor
- Taisho Pharmaceutical Co., Ltd.
Hyperphosphatemia Patients on Hemodialysis
A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis
A phase 3, randomized, placebo-controlled, double-blind study of TS-172 in hyperphosphatemia
- Trial name
- NCT06745531
- Testing
- TS-172 20~60 mg/day
- Where
- Japan
- Volunteers
- 101 people
- Sponsor
- Taisho Pharmaceutical Co., Ltd.
End Stage Renal Disease (ESRD)
Multi-Site STARgraft (10401) Trial
This is a multi-site, single-blind with parallel group, randomized controlled trial of Healionics STARgraft (10401) vascular graft for hemodialysis access compared with a market-leading commercially available ePTFE vascular graft…
- Trial name
- NCT07557862
- Testing
- STARgraft (10401), Gore Propaten
- Where
- 7 sites in Brazil, Colombia
- Volunteers
- 111 people
- Sponsor
- Healionics Corporation
End Stage Renal Disease
Safety and Immunogenicity of HEPLISAV™ a Hepatitis B Virus Vaccine in Adults on Hemodialysis
The purpose of this study is to compare the immune response to HEPLISAV™ booster injection with the immune response to Engerix-B® and Fendrix® booster vaccinations among patients with end stage renal disease (ESRD) on…
- Trial name
- NCT01195246
- Testing
- HEPLISAV, Engerix-B, Fendrix
- Where
- 19 sites in Germany
- Volunteers
- 155 people
- Sponsor
- Dynavax Technologies Corporation